Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082492 | 1.00 | TAAR1 (1.00) | TAAR1CYP2D6 | |
| SCHEMBL503168 | 1.00 | TAAR1 (1.00) | TAAR1CYP2D6 | |
| SCHEMBL2080238 | 0.92 | TAAR1 (0.85) | TAAR1CYP2D6 | |
| SCHEMBL2080236 | 0.92 | TAAR1 (0.85) | TAAR1CYP2D6 | |
| SCHEMBL12777510 | 0.91 | TAAR1 (0.83) | TAAR1CYP2D6 | |
| SCHEMBL12777509 | 0.91 | TAAR1 (0.83) | TAAR1CYP2D6 | |
| SCHEMBL2079021 | 0.90 | TAAR1 (0.81) | TAAR1CYP2D6 | |
| SCHEMBL2079017 | 0.90 | TAAR1 (0.81) | TAAR1CYP2D6 | |
| SCHEMBL2082816 | 0.89 | TAAR1 (0.79) | TAAR1CYP2D6 | |
| SCHEMBL2081571 | 0.89 | TAAR1 (0.79) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-10098893-B2 | Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457 | NORTHWESTERN UNIVERSITY (US) | 2018-10-16 | — | — | US | claimed |
| US-20150099741-A1 | DIAGNOSING AND TREATING PATIENTS HAVING PSYCHIATRIC DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2015-04-09 | — | — | US | claimed |
| EP-2121641-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | claimed |
| EP-2600853-A1 | COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-12 | — | — | EP | claimed |
| WO-2012016879-A1 | COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-09 | — | — | WO | claimed |
| US-20120028964-A1 | PHARMACEUTICAL COMBINATION | SEMINIS VEGETABLE SEEDS, INC. | 2012-02-02 | — | — | US | claimed |
| US-7902238-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | claimed |
| EP-2121641-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-11-25 | — | — | EP | claimed |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | US | claimed |
| WO-2008098857-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-21 | — | — | WO | claimed |
| WO-2026106796-A1 | SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS | FOLLEA INTERNATIONAL (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12590077-B2 | Short-acting monoamine releasers | Solvonics Therapeutics Ireland Holdings Limited (IE) | 2026-03-31 | — | — | US | disclosed |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INT (US) | 2026-02-12 | — | — | US | disclosed |
| EP-2121641-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | US | disclosed |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | US | disclosed |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008098857-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028964-A1 | PHARMACEUTICAL COMBINATION | TAAR1, TAAR5, MC2R | TAAR1 1/4885CYP2D6 308/4885 |
| US-12590077-B2 | Short-acting monoamine releasers | SLC6A2, NPY2R, SLC6A3 | TAAR1 30/4885CYP2D6 320/4885 |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | DYRK4, DYRK2, STRA6 | TAAR1 370/4885CYP2D6 3065/4885 |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPSR1 | TAAR1 1/4885CYP2D6 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.